Terapia allocates 750,000 euros for research

Terapia Cluj-Napoca pharmaceutical company will invest 750,000 euros in a bio-equivalence centre to be finalised by mid this month. The investment will allow the company to double its bio-equivalence research capacity. The bio-equivalence research is a necessary stage in registering generic products on the market, which are the equivalent of original drugs whose patent expired. Normally, there is no difference between a patent and a generic drug in terms of therapeutic effects. “The development of the company”s activity and the expansion of its product portfolio has made increasing the bio-equivalence department”s capacity necessary”, stated Stephen Stead, Terapia general manager. The new bio-equivalence centre will be an extension of the old one, inaugurated in 2003. Generic products for which bio-equivalence research has been conducted are therapeutically interchangeable with patent drugs included in the lists of compensated drugs, and this drives sales up. ZF